OJSC Pharmstandard PHST Acquisition

  OJSC Pharmstandard (PHST) - Acquisition

RNS Number : 7052R
OJSC Pharmstandard
21 November 2012




Pharmstandard OJSC announces the Acquisition of a 100% stake in "LEKKO" CJSC.

Moscow, November 21, 2012  -O JSC Pharmstandard  announces the acquisition  of 
100% stake in "LEKKO" CJSC.

On September 6, 2012 Russia's  Federal Antimonopoly Service (FAS) has  granted 
approval for OJSC Pharmstandard's bid to acquire 100% of the voting shares of
CJSC "LEKKO".

"LEKKO" CJSC is a Russian innovative  company which performs in the field  of 
research and development of highly effective drugs as well as their production
and distribution. The company has an 18-year track record of successful market
presence and it's  products are a  result of years  of successful  investments 
into promising scientific researches in the field of traditional medicine.

"LEKKO" CJSC production facilities are located in Volginsky village  (Vladimir 
region). Annual  output  amounts to  50  million packs  of  11  pharmaceutical 
products. The company employs 400 highly-qualified professionals in the  field 
of medicine and  pharmacy, biology  and chemistry,  management, marketing  and 
technology.

"LEKKO" CJSC  2011 audited  revenues amounted  to RUR684.4m.  3Q2012  revenues 
reached RUR357.6m.

Pharmstandard OJSC uses  LEKKO facilities  to produce  Rinostop® and  Acipol®. 
3Q2012 sales of these drugs amounted to RUR111.6m and RUR266.04m accordingly.

Pharmstandard OJSC management believes that the acquisition of LEKKO is highly
effective for further successful production  of Rinostop® and Acipol® as  well 
as for the expansion of business in general.

Irina Bakhturina
Investor Relations
OJSC Pharmstandard
+7 495 970 00 30 ext.2824
www.pharmstd.com

About the Pharmstandard group of companies

The main sphere of  activity of the  enterprises comprising the  Pharmstandard 
group of companies,  are developing and  manufacturing of high-quality  modern 
pharmaceutical products which meet the  requirements of the healthcare  system 
and the expectations of patients.

The most  well-known Pharmstandard  products today  are Arbidol®,  Complivit®, 
Pentalgin®,  Flucostat®,  Phosphoglive®,   Amixin®,  Afobazol®,  Rastan®   and 
Biosulin®. The Pharmstandard  group of  companies manufactures  more than  250 
pharmaceutical  products,   including   medicines   for   the   treatment   of 
cardio-vascular    diseases,    diabetes,    growth    hormone     deficiency, 
gastroenterological, neurological, contagious  diseases, metabolic  disorders, 
cancer and other diseases. More  than 100 Pharmstandard products (taking  into 
account all forms and dosages) are included in the list of Vital and Essential
Pharmaceuticals.

In the period from 2004 to 2011 more than 60 new pharmaceutical products  were 
developed  by  Pharmstandard,  in   co-operation  with  the  leading   Russian 
scientific centres. Pharmstandard is a participant in a joint  bio-engineering 
project, Generium, whose objective is the development of socially  significant 
pharmaceutical products within the  framework of the  state program of  import 
substitution.

By 2011 the Сompany's aggregate production capacity has reached more than 1,46
billion packages per year. The production capacity of the Pharmstandard  group 
of   companies   comprises    four   modern    pharmaceutical   plants:    JSC 
Pharmstandard-Leksredstva  (Kursk),  JSC   Pharmstandard-UfaVita  (Ufa),   JSC 
Pharmstandard-Tomskhimpharm  (Tomsk),   JSC   Pharmstandard-Biolek   (Kharkov, 
Ukraine) and  the  medical  equipment  and tools  plant  JSC  TZMOI  (Tyumen); 
Pharmstandard LLC is responsible for the purchase and supply of raw  materials 
for manufacturing of pharmaceutical products  at the production facilities  of 
the Pharmstandard group of companies.

All the production facilities  of the Pharmstandard  group of companies  fully 
comply with  Russian national  standards, while  six production  lines at  JSC 
Pharmstandard-Leksredstva have  already  received certificates  of  compliance 
with the EU GMP standards. All the plants are expected to convert to  European 
GMP standards by  2014, according to  the schedule approved  by the  company's 
management.

On 4 May 2007  Pharmstandard placed its shares  during IPO on Russian  Trading 
System (RTS), Moscow Interbank Currency Exchange (MICEX) and Global Depositary
Receipts (GDR) at London Stock Exchange (LSE).



                               www.pharmstd.com































































                                      

                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


ACQEADFFAFPAFFF -0- Nov/21/2012 14:00 GMT
 
Press spacebar to pause and continue. Press esc to stop.